Sinusitis: why distinguishing between inflammatory forms (including non-allergic) and purulent infection is essential

Sinusitis is one of the most common conditions seen in ENT practice, yet it remains widely misunderstood. Too often, all forms of sinusitis are treated the same way, leading to ineffective therapies or even harm. In reality, sinusitis is not a single disease: there are profoundly different types that require equally different approaches.

In this article, we clarify the fundamental distinction between inflammatory sinusitis (with and without an allergic component) and purulent infectious sinusitis, and introduce a new active substance – Cucurbitacins B-D-I-E – which represents an absolute novelty in the therapeutic landscape for purulent forms.

What is sinusitis?

Sinusitis is an inflammation of the mucosa lining the paranasal sinuses – the bony cavities located around the nasal passages. It can present in an acute form (symptoms lasting less than 4 weeks) or become chronic when symptoms persist for more than 12 weeks despite treatment.

Causes are numerous: viral infections (often secondary to the common cold), bacterial infections, allergies, anatomical variants (deviated nasal septum, polyps), environmental factors such as pollution, as well as non-allergic inflammatory mechanisms.

Typical symptoms of sinusitis include facial pain and pressure, frontal headache, reduced sense of smell, bad breath, and a productive cough (especially at night). However, the most important feature to observe is the quality of nasal secretions.

The crucial difference: inflammatory sinusitis vs purulent infectious sinusitis

Inflammatory sinusitis (non-purulent)

In inflammatory forms, mucosal inflammation is present but there is no pus. Secretions are generally clear, white, or serous. This category includes:

• Allergic sinusitis (IgE-mediated)
• Non-allergic, cell-mediated sinusitis, including:
• NARMA (Non-Allergic Rhinitis with Mast cell activation)
• NARNE (Non-Allergic Rhinitis with Neutrophil activation)
• NARES (Non-Allergic Rhinitis with Eosinophilia Syndrome)
• NARESMA (mixed form with eosinophils and mast cells)

These non-allergic forms are often underdiagnosed and respond poorly to antihistamines; they instead require a specific anti‑inflammatory approach and control of triggering factors (environmental irritants, temperature changes, certain medications).

Purulent infectious sinusitis

In purulent forms, inflammation is driven by a bacterial infection (or occasionally fungal) and secretions are thick, yellow or greenish (pus). Stagnation of purulent material within the sinuses is promoted by an impairment of mucociliary clearance – the microscopic “brush” system that normally removes mucus.

In summary: not all sinusitis involves pus. In inflammatory forms (allergic or non‑allergic cell‑mediated), mucus is clear; in purulent forms, thick yellow‑green secretions indicate an active infection that must be mechanically and biologically cleared.

Why purulent infectious sinusitis (acute and chronic) requires a targeted approach

In purulent infectious sinusitis – both acute and chronic – pus stagnates within the paranasal sinuses due to inefficient mucociliary clearance. The cilia of the respiratory epithelium can no longer effectively move secretions outward, creating an ideal environment for bacterial growth.

• Acute purulent sinusitis: develops rapidly, often after a poorly managed cold or bacterial superinfection.
• Chronic purulent sinusitis: persists for more than 12 weeks, with recurrent purulent discharge and progressive mucosal damage.

In both cases, it is essential to thin the pus, restore ciliary motility, and reduce mucosal oedema. Without these interventions, the infection tends to self‑perpetuate and the risk of chronicity rises significantly.

Cucurbitacins B-D-I-E: a new active substance in the treatment of purulent infectious sinusitis

Recent pharmacological research has developed a new plant‑derived active substance – Cucurbitacins B-D-I-E, extracted from Ecballium elaterium – which acts through an innovative and globally unique mechanism of action, specifically designed for purulent infectious sinusitis (acute and chronic).

From an academic and functional perspective, Cucurbitacins B-D-I-E intervene on three key pathogenetic levels:

1. Surfactant and thinning effect
   The molecules act on the surface tension of muco‑purulent secretions, reducing viscosity and promoting dilution. Pus becomes more fluid and therefore easier to evacuate.
2. Restoration of ciliary motility
   The Cucurbitacin‑containing solution induces electrolyte and osmotic changes at the epithelial level, which help reactivate ciliary beating and thus mucociliary clearance.
3. Reduction of mucosal oedema
   The action on mucosal cells results in physiological decongestion, reopening of the sinus ostia and restoration of sinus pneumatisation (normal air pressure within the sinuses).

Clinical note: in confirmed purulent sinusitis, a doctor may prescribe antibiotic therapy. Cucurbitacins B-D-I-E do not replace antibiotics but serve as a well‑documented adjunct to improve mechanical drainage and reduce the risk of chronic evolution.

When are Cucurbitacins B-D-I-E indicated (and when not)?

This new active substance is specifically indicated in purulent infectious rhinosinusitis, both acute and chronic, in the presence of:

• Nasal or post‑nasal discharge of thick mucus (yellow, greenish or white)
• Craniofacial pain corresponding to one or more paranasal sinuses
• Reduced sense of smell (hyposmia)
• Nasal congestion (especially unilateral), hearing loss, or nosebleeds

It is not indicated in inflammatory sinusitis (clear secretions, allergic or cell‑mediated origin such as NARMA, NARNE, NARES, NARESMA). In those cases, it would be ineffective.

A practical rule to distinguish sinusitis types

A new tool in the management of purulent sinusitis

Cucurbitacins B-D-I-E represent one of the rare therapeutic innovations able to act simultaneously on pus thinning, ciliary function restoration, and oedema reduction in purulent infectious sinusitis. A globally unique active substance that can make a real difference, especially in recurrent or chronic‑prone forms.

To learn more about sinusitis and explore available treatment options
👉 Visit our sinusitis information page (https://www.neviabiotech.it/en/collections/sinusitis)

If you are unsure about your type of sinusitis, consult your GP or an ENT specialist. A correct diagnosis – distinguishing between inflammatory and purulent forms – is the first step towards effective treatment.

Disclaimer: This article is for informational purposes only. Any medical device mentioned should be used in accordance with the instructions for use and after consulting a healthcare professional.